Literature DB >> 26606155

Clinical characteristics and outcomes of patients with community-acquired, health-care-associated and hospital-acquired empyema.

Yasuko Koma1, Sayaka Inoue1, Nao Oda1, Naoya Yokota1, Koji Tamai1, Yusuke Matsumoto1, Nobuhiko Okada1, Akiko Otsuka1, Nariyasu Nakashima1, Daiki Masuya1, Hirofumi Matsuoka1, Harukazu Yoshimatsu1, Yujiro Suzuki1.   

Abstract

BACKGROUND AND AIMS: Patients with pneumonia, a common cause of empyema, are stratified based on their risk factors, and the treatment of empyema might benefit from this risk stratification.
METHODS: The etiology, bacteriologic profile and outcome of patients diagnosed with empyema in Shinko Hospital between May 2005 and October 2013 were retrospectively studied. The patients were stratified according to whether they had community-acquired empyema (CAE), health-care-associated empyema (HCAE) or hospital-acquired empyema (HAE).
RESULTS: The study included 81 patients, 25 CAE, 40 HCAE and 16 HAE. The comorbidity rate was highest among HAE patients (100%), followed by 95% of HCAE and 72% of CAE patients (P = 0.005). The rates of cancer and central nervous system (CNS) disease were higher in patients with HCAE and HAE than in patients with CAE (P = 0.030, P = 0.018, respectively). Pleural fluid cultures were positive in 58/81 patients. Streptococcus species were the most common organisms cultured from CAE (12/15) and HCAE patients (17/30), but not from HAE patients (3/13). Anaerobic organisms were cultured from 3 CAE, 5 HCAE and 3 HAE patients. Methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa were only cultured from HCAE and HAE patients. The mortality rates were higher in HCAE (18%) and HAE (50%) than in CAE (4%) patients (log-rank test: P = 0.0012).
CONCLUSIONS: Half of patients with empyema were HCAE patients, who had comorbidities, bacteriological profile and outcome different from CAE patients. The patient with HCAE should be differentiated from CAE patient, and the stratification of patients based on risk factors may be useful for treatment strategy.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  community-acquired; empyema; health care-associated; hospital-acquired; outcomes

Mesh:

Year:  2015        PMID: 26606155     DOI: 10.1111/crj.12416

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  4 in total

1.  The effect of Cyclic-di-GMP on biofilm formation by Pseudomonas aeruginosa in a novel empyema model.

Authors:  Li Zhang; Jinlong Li; Jinhua Liang; Zhenqiang Zhang; Qingjun Wei; Ke Wang
Journal:  Ann Transl Med       Date:  2020-09

2.  A systematic review of comorbidities and outcomes of adult patients with pleural infection.

Authors:  Tamsin N Cargill; Maged Hassan; John P Corcoran; Elinor Harriss; Rachelle Asciak; Rachel M Mercer; David J McCracken; Eihab O Bedawi; Najib M Rahman
Journal:  Eur Respir J       Date:  2019-10-01       Impact factor: 16.671

3.  Identification of Microbiome Etiology Associated With Drug Resistance in Pleural Empyema.

Authors:  Zhaoyan Chen; Hang Cheng; Zhao Cai; Qingjun Wei; Jinlong Li; Jinhua Liang; Wenshu Zhang; Zhijian Yu; Dongjing Liu; Lei Liu; Zhenqiang Zhang; Ke Wang; Liang Yang
Journal:  Front Cell Infect Microbiol       Date:  2021-03-16       Impact factor: 5.293

4.  Mortality Among Hospitalized Patients With Pleural Effusions. A Multicenter, Observational, Prospective Study.

Authors:  Eleftherios Markatis; Garifallia Perlepe; Andreas Afthinos; Konstantinos Pagkratis; Charalampos Varsamas; Eleftheria Chaini; Ilias C Papanikolaou; Konstantinos I Gourgoulianis
Journal:  Front Med (Lausanne)       Date:  2022-02-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.